Febuxostat Apexbio

Febuxostat
A5926-100 100 mg
EUR 714
Description: IC50: Febuxostat displayed potent mixed-type inhibition of the activity of xanthine oxidase (XO), with Ki value of 0.6 nM [1]. Febuxostat was also reported to be 1000-fold (IC50=1.8 nM) more potent than allopurinol (IC50= 2.9 ?M) at inhibiting XO-dependent uric acid formation [2].

Apexbio Reagents Laboratories manufactures the febuxostat apexbio reagents distributed by Genprice. The Febuxostat Apexbio reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Apexbio Reagents. Other Febuxostat products are available in stock. Specificity: Febuxostat Category: Apexbio

Amyloid ?-Protein (1-15)
1 mg
EUR 135.6
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid ?-Protein (1-15)
10 mg
EUR 442.8
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid ?-Protein (1-15)
25 mg
EUR 595.2
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid ?-Protein (1-15)
5 mg
EUR 289.2
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid Precursor C-Terminal Peptide
1 mg
EUR 135.6
Description: Amyloid precursor c-terminal peptide (APP) (C86H118N20O27S) has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. Although it has been implicated as a regulator of synapse formation, neural plasticity and iron export, the primary function of APP is not known.

Amyloid Precursor C-Terminal Peptide
10 mg
EUR 442.8
Description: Amyloid precursor c-terminal peptide (APP) (C86H118N20O27S) has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. Although it has been implicated as a regulator of synapse formation, neural plasticity and iron export, the primary function of APP is not known.

Amyloid Precursor C-Terminal Peptide
25 mg
EUR 595.2
Description: Amyloid precursor c-terminal peptide (APP) (C86H118N20O27S) has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. Although it has been implicated as a regulator of synapse formation, neural plasticity and iron export, the primary function of APP is not known.

Human Samples information

Beta-Sheet Breaker Peptide iA?5
A1005-25 25 mg
EUR 205.2
Description: Beta-Sheet Breaker Peptide iA?5 (C33H43N5O8), with the sequence H-Leu-Pro-Phe-Phe-Asp-OH, has been shown to inhibit amyloidogenesis in rat brain models.

Beta-Sheet Breaker Peptide iA?5
A1005-5 5 mg
EUR 122.4
Description: Beta-Sheet Breaker Peptide iA?5 (C33H43N5O8), with the sequence H-Leu-Pro-Phe-Phe-Asp-OH, has been shown to inhibit amyloidogenesis in rat brain models.

Angiotensin I (human, mouse, rat)
A1006-10 10 mg
EUR 199.2
Description: Angiotensin I (Ang I) (C62H89N17O14), with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, is formed by the action of renin on angiotensinogen.

Angiotensin I (human, mouse, rat)
A1006-25 25 mg
EUR 254.4
Description: Angiotensin I (Ang I) (C62H89N17O14), with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, is formed by the action of renin on angiotensinogen.

Angiotensin I (human, mouse, rat)
A1006-5 5 mg
EUR 142.8
Description: Angiotensin I (Ang I) (C62H89N17O14), with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, is formed by the action of renin on angiotensinogen.

Angiotensin 1/2 (1-9)
A1007-10 10 mg
EUR 199.2
Description: Angiotensin I/II (1-9) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS) containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.

Angiotensin 1/2 (1-9)
A1007-25 25 mg
EUR 254.4
Description: Angiotensin I/II (1-9) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS) containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.

Angiotensin 1/2 (1-9)
A1007-5 5 mg
EUR 142.8
Description: Angiotensin I/II (1-9) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS) containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.

Anti-Inflammatory Peptide 1
A1008-10 10 mg
EUR 199.2
Description: Anti-Inflammatory Peptide 1 (C45H82N12O14S2), with the sequence H-Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH, belongs to the group of synthetic oligopeptides corresponding to a region of high amino-acid sequence similarity between uteroglobin and lipocortin I

Anti-Inflammatory Peptide 1
A1008-25 25 mg
EUR 254.4
Description: Anti-Inflammatory Peptide 1 (C45H82N12O14S2), with the sequence H-Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH, belongs to the group of synthetic oligopeptides corresponding to a region of high amino-acid sequence similarity between uteroglobin and lipocortin I

Anti-Inflammatory Peptide 1
A1008-5 5 mg
EUR 142.8
Description: Anti-Inflammatory Peptide 1 (C45H82N12O14S2), with the sequence H-Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH, belongs to the group of synthetic oligopeptides corresponding to a region of high amino-acid sequence similarity between uteroglobin and lipocortin I

ANP (1-11), rat
A1009-1 1 mg
EUR 100.8
Description: Atrial Natriuretic Peptide (ANP) (C49H84N20O15S) has the sequence of H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, is a 28 amino acid peptide that is synthesized, stored, and released by atrial myocytes in response to atrial distension, endothelin, and sympathetic stimulation.

ANP (1-11), rat
A1009-10 10 mg
EUR 268.8
Description: Atrial Natriuretic Peptide (ANP) (C49H84N20O15S) has the sequence of H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, is a 28 amino acid peptide that is synthesized, stored, and released by atrial myocytes in response to atrial distension, endothelin, and sympathetic stimulation.

ANP (1-11), rat
A1009-25 25 mg
EUR 351.6
Description: Atrial Natriuretic Peptide (ANP) (C49H84N20O15S) has the sequence of H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, is a 28 amino acid peptide that is synthesized, stored, and released by atrial myocytes in response to atrial distension, endothelin, and sympathetic stimulation.

ANP (1-11), rat
A1009-5 5 mg
EUR 184.8
Description: Atrial Natriuretic Peptide (ANP) (C49H84N20O15S) has the sequence of H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, is a 28 amino acid peptide that is synthesized, stored, and released by atrial myocytes in response to atrial distension, endothelin, and sympathetic stimulation.

Myelopeptide-2 (MP-2)
A1010-1 1 mg
EUR 115.2
Description: Myelopeptide-2 (MP-2) (C41H57N7O8), with the sequence Leu-Val-Val-Tyr-Pro-Trp, is originally isolated from the supernatant of porcine bone marrow cell culture, and is able to restore the mitogen responsiveness of human T lymphocytes inhibited by conditioned medium

Myelopeptide-2 (MP-2)
A1010-10 10 mg
EUR 338.4
Description: Myelopeptide-2 (MP-2) (C41H57N7O8), with the sequence Leu-Val-Val-Tyr-Pro-Trp, is originally isolated from the supernatant of porcine bone marrow cell culture, and is able to restore the mitogen responsiveness of human T lymphocytes inhibited by conditioned medium